A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over ...
Growing at a rate of knots from the Cambridge Biomedical Campus, AstraZeneca hoisted its market cap to £183.58 billion and ...
Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total Revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback